Discount Drug Mart launches fleet of Kodak photo printing solutions throughout Ohio
MEDINA, Ohio Eastman Kodak Co. has signed an exclusive, multi-year contract with an Ohio-owned and operated regional drug chain.
Discount Drug Mart will deploy Kodak Picture Kiosk G4 Digital Stations and Kodak Adaptive Picture Exchange thermal dry lab systems into all 70 Discount Drug Mart stores throughout Ohio.
As part of the new contract, Discount Drug Mart will be upgrading its fleet of older Kodak consumer order stations to Kodak G4 Stations, which will allow Discount Drug Mart customers to take advantage of a wide range of premium photo creation products, including Kodak Picture Movie DVDs, Kodak Picture CDs, enlargements, collage prints, calendars, invitations and greeting cards. Discount Drug Mart will also be increasing the number of Kodak Picture Kiosks per store, allowing multiple customers to experience and create prints and premium products faster and more easily. The newer G4 model can create standard 4 x 6 prints up to 70% faster than older kiosk systems.
“Giving our customers an exceptional photo creation experience is an integral part of our mission, and we felt that Kodak, as the market leader, best delivered that experience,” said John Graycar, director photo operations at Discount Drug Mart. “Kodak is providing both an integrated suite of photo finishing solutions and the technical and business expertise needed to enable all our locations with one-stop access to award winning photo products and services.”
Wild Child provides natural way to ‘Quit Nits’
LOS ANGELES Wild Child, an Australian-based natural healthcare products company showcased its Quit Nits head lice products at ECRM Health Care.
According to the company, from a survey of 1,002 parents of children ages 6 to 13, 69% of parents said it was extremely important that any lice solution they buy not contain any toxic chemicals. And 61% responded that the product should be safe for use by pregnant women. In addition, over 3-in-5 parents (64%) were bothered by the fact that many head lice treatments currently contain toxic ingredients with possible negative side effects.
Teva launches ‘Patient First’ project
WASHINGTON The world’s largest generic drug maker has started an initiative to tell stories of Americans who have difficulty paying for their prescription medications, and push for a regulatory approval pathway for biosimilars.
Teva Pharmaceuticals USA announced Thursday the “Patient First” project, part of its broader Year of Affordable Healthcare campaign.
One story is of Rob Day, who was diagnosed at age 19 with the rare blood disorder paroxysmal nocturnal hemoglobinuria, for which he must take an unspecified biotech drug that costs him $389,000 a year. Teva said a Food and Drug Administration approval pathway for biosimilars would help lower prices for drugs like the one Day takes.